TrademarkOpen
Search / US trademark / 98365237
US trademark / service mark

EAPHARMA

Published for opposition

Status timeline

  1. 19 Jan 2024
    Application filed
    New Application Entered
  2. 14 Aug 2024
    Assigned to an examining attorney
    Assigned To Examiner
  3. 14 Aug 2024
    Office action issued
    Non-Final Action Written
  4. 25 Oct 2024
    Response to office action filed
    Teas Response To Office Action Received
  5. 19 Nov 2024
    Examination suspended
    Suspension Letter Written
  6. 20 Jul 2026
    Approved for publication
    Approved For Pub - Principal Register
  7. 18 Aug 2026
    Published for opposition
    Published For Opposition
All 23 USPTO events
2026-08-18Published For Opposition
2026-08-18Official Gazette Publication Confirmation E-Mailed
2026-08-12Notification Of Notice Of Publication E-Mailed
2026-07-20Approved For Pub - Principal Register
2026-06-08Suspension Checked - To Attorney For Action
2025-12-09Report Completed Suspension Check Case Still Suspended
2025-06-17Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
2025-06-17Attorney/Dom.rep.revoked And/Or Appointed
2025-06-17Teas Change Of Correspondence Received
2025-06-02Report Completed Suspension Check Case Still Suspended
2024-11-19Suspension Letter Written
2024-11-19Letter Of Suspension E-Mailed
2024-11-19Notification Of Letter Of Suspension E-Mailed
2024-10-25Teas Response To Office Action Received
2024-10-25Correspondence Received In Law Office
2024-10-25Teas/Email Correspondence Entered
2024-08-14Assigned To Examiner
2024-08-14Non-Final Action Written
2024-08-14Non-Final Action E-Mailed
2024-08-14Notification Of Non-Final Action E-Mailed
2024-06-15New Application Office Supplied Data Entered
2024-06-15Notice Of Design Search Code E-Mailed
2024-01-19New Application Entered

Goods & services

Class 5 Pharmaceuticals & supplements

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, inflammatory, namely except inflammatory bronchial disease, metabolic, neurodegenerative, neurological, psychiatric, oncological, and viral diseases and disorders; Pharmaceutical preparations for the treatment of liver diseases and disorders, erectile dysfunction, sexual dysfunction, cancer, pain, and diabetes; Reagent paper for medical purposes

Class 42 Technology & SaaS

Pharmaceutical research and development, namely, pharmaceutical testing, inspection and research

Class 44 Medical & beauty services

Medical information; Providing health care information via a global computer network

Source & freshness

Source: USPTO Trademark Applications bulk data. This record was last updated by the USPTO file dated 18 Aug 2026; the index was built on 20 Nov 2026 and covers USPTO data through 31 Aug 2026. Open the official USPTO record (TSDR) → If the two differ, the USPTO record is correct.